To assess the association of metabolic syndrome components with Lp-PLA2 activity, we further found that significant difference in Lp-PLA2 was obtained between patients with three (n = 89) and four (n = 28) disorders of metabolic syndrome (38.79 ± 9.22 umol/min/mL vs. 30.60 ± 9.58 umol/min/mL, P < 0.01). This evidence concerns the gene PLA2G7 and metabolic syndrome.